180 Life Sciences (ATNF) Competitors $1.33 +0.44 (+49.44%) Closing price 03:59 PM EasternExtended Trading$1.32 -0.02 (-1.13%) As of 05:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ATNF vs. MTEX, ALLR, NAII, CMMB, EDSA, SLGL, EQ, LPCN, CING, and UBXShould you be buying 180 Life Sciences stock or one of its competitors? The main competitors of 180 Life Sciences include Mannatech (MTEX), Allarity Therapeutics (ALLR), Natural Alternatives International (NAII), Chemomab Therapeutics (CMMB), Edesa Biotech (EDSA), Sol-Gel Technologies (SLGL), Equillium (EQ), Lipocine (LPCN), Cingulate (CING), and Unity Biotechnology (UBX). These companies are all part of the "pharmaceutical products" industry. 180 Life Sciences vs. Mannatech Allarity Therapeutics Natural Alternatives International Chemomab Therapeutics Edesa Biotech Sol-Gel Technologies Equillium Lipocine Cingulate Unity Biotechnology Mannatech (NASDAQ:MTEX) and 180 Life Sciences (NASDAQ:ATNF) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, profitability, analyst recommendations, dividends, community ranking and media sentiment. Is MTEX or ATNF more profitable? 180 Life Sciences has a net margin of 0.00% compared to Mannatech's net margin of -1.26%. Mannatech's return on equity of -15.62% beat 180 Life Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Mannatech-1.26% -15.62% -3.76% 180 Life Sciences N/A -558.93%-54.10% Does the MarketBeat Community prefer MTEX or ATNF? Mannatech received 325 more outperform votes than 180 Life Sciences when rated by MarketBeat users. Likewise, 77.49% of users gave Mannatech an outperform vote while only 18.18% of users gave 180 Life Sciences an outperform vote. CompanyUnderperformOutperformMannatechOutperform Votes32777.49% Underperform Votes9522.51% 180 Life SciencesOutperform Votes218.18%Underperform Votes981.82% Which has more risk & volatility, MTEX or ATNF? Mannatech has a beta of 0.98, meaning that its stock price is 2% less volatile than the S&P 500. Comparatively, 180 Life Sciences has a beta of 0.27, meaning that its stock price is 73% less volatile than the S&P 500. Which has preferable valuation & earnings, MTEX or ATNF? Mannatech has higher revenue and earnings than 180 Life Sciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMannatech$117.87M0.16-$2.24M$1.337.66180 Life SciencesN/AN/A-$19.93MN/AN/A Does the media favor MTEX or ATNF? In the previous week, 180 Life Sciences had 1 more articles in the media than Mannatech. MarketBeat recorded 4 mentions for 180 Life Sciences and 3 mentions for Mannatech. Mannatech's average media sentiment score of 0.96 beat 180 Life Sciences' score of 0.17 indicating that Mannatech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mannatech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive 180 Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals & insiders believe in MTEX or ATNF? 13.0% of Mannatech shares are held by institutional investors. Comparatively, 4.1% of 180 Life Sciences shares are held by institutional investors. 41.5% of Mannatech shares are held by insiders. Comparatively, 0.2% of 180 Life Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. SummaryMannatech beats 180 Life Sciences on 10 of the 12 factors compared between the two stocks. Get 180 Life Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ATNF and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATNF vs. The Competition Export to ExcelMetric180 Life SciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.90M$6.71B$5.48B$7.93BDividend YieldN/A3.05%5.11%4.22%P/E RatioN/A7.3522.6018.54Price / SalesN/A241.21397.55103.37Price / CashN/A65.8538.1834.62Price / Book-5.546.486.744.25Net Income-$19.93M$143.41M$3.22B$248.18M7 Day Performance54.67%2.13%1.55%1.27%1 Month Performance40.00%7.02%4.04%3.78%1 Year Performance-33.17%-2.68%15.63%5.28% 180 Life Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATNF180 Life SciencesN/A$1.33+49.4%N/A-58.6%$6.90MN/A0.007Short Interest ↑News CoverageHigh Trading VolumeMTEXMannatech1.6187 of 5 stars$9.40-1.1%N/A+26.3%$17.87M$117.87M-11.60250Short Interest ↓ALLRAllarity Therapeutics0.295 of 5 stars$1.03+9.6%N/A-96.9%$17.53MN/A0.0010NAIINatural Alternatives International0.9823 of 5 stars$2.61-6.1%N/A-52.0%$17.21M$121.85M-2.02290High Trading VolumeCMMBChemomab Therapeutics3.579 of 5 stars$1.16+3.6%$9.00+675.9%+92.9%$16.66MN/A-1.1620Upcoming EarningsShort Interest ↓News CoverageEDSAEdesa Biotech3.103 of 5 stars$2.38+5.3%$21.00+782.4%-47.6%$16.64MN/A-1.2720Short Interest ↓Positive NewsSLGLSol-Gel Technologies2.3707 of 5 stars$0.59+6.4%$5.00+754.7%+6.7%$16.30M$11.71M-1.7250News CoverageGap DownHigh Trading VolumeEQEquillium2.8051 of 5 stars$0.46-3.7%$3.00+559.1%-71.8%$16.26M$41.10M-3.2540Upcoming EarningsShort Interest ↓Positive NewsGap DownLPCNLipocine2.495 of 5 stars$3.01+0.3%$10.00+232.2%-28.4%$16.10M$11.20M-3.9610Upcoming EarningsAnalyst ForecastNews CoverageCINGCingulate2.5213 of 5 stars$4.07-4.0%$30.67+653.5%+350.8%$16.04MN/A-0.2820Short Interest ↑News CoverageUBXUnity Biotechnology4.1227 of 5 stars$0.94-3.1%$5.33+467.6%-26.6%$15.85M$240,000.00-0.7260Analyst RevisionNews Coverage Related Companies and Tools Related Companies MTEX Competitors ALLR Competitors NAII Competitors CMMB Competitors EDSA Competitors SLGL Competitors EQ Competitors LPCN Competitors CING Competitors UBX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ATNF) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredTrump announcement boosts “next Bitcoin”President Trump just made his first big crypto move ... Announcing the creation of a national strategic re...Weiss Ratings | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredMassive dollar overhaul underway in D.C.?Trump's plan to save the U.S. Dollar The U.S. Dollar is crashing, and our reserve currency status is now in...Stansberry Research | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 180 Life Sciences Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share 180 Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ATNF Stock Free ATNF Stock Alerts